Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1921 1
1924 2
1925 1
1926 1
1928 1
1942 1
1947 2
1948 2
1950 6
1951 4
1952 4
1953 4
1954 4
1955 3
1956 4
1957 2
1958 1
1960 1
1961 2
1962 4
1963 5
1964 3
1965 3
1966 10
1967 14
1968 24
1969 12
1970 15
1971 11
1972 17
1973 9
1974 22
1975 26
1976 33
1977 27
1978 24
1979 19
1980 37
1981 21
1982 33
1983 41
1984 36
1985 30
1986 42
1987 46
1988 61
1989 42
1990 41
1991 58
1992 45
1993 75
1994 66
1995 58
1996 52
1997 69
1998 64
1999 76
2000 77
2001 85
2002 94
2003 73
2004 98
2005 80
2006 108
2007 112
2008 96
2009 83
2010 102
2011 109
2012 81
2013 84
2014 97
2015 92
2016 92
2017 80
2018 81
2019 98
2020 112
2021 108
2022 74
2023 31
Text availability
Article attribute
Article type
Publication date

Search Results

3,232 results
Results by year
Filters applied: . Clear all
Page 1
Bone metastasis: mechanisms, therapies, and biomarkers.
Clézardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB, Holen I. Clézardin P, et al. Among authors: coleman r. Physiol Rev. 2021 Jul 1;101(3):797-855. doi: 10.1152/physrev.00012.2019. Epub 2020 Dec 24. Physiol Rev. 2021. PMID: 33356915 Free article. Review.
Bone metastases.
Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R, Costa L. Coleman RE, et al. Nat Rev Dis Primers. 2020 Oct 15;6(1):83. doi: 10.1038/s41572-020-00216-3. Nat Rev Dis Primers. 2020. PMID: 33060614 Review.
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.
Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, Gebski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A. Ramirez PT, et al. Among authors: coleman rl. N Engl J Med. 2018 Nov 15;379(20):1895-1904. doi: 10.1056/NEJMoa1806395. Epub 2018 Oct 31. N Engl J Med. 2018. PMID: 30380365 Clinical Trial.
Low-grade serous ovarian cancer: State of the science.
Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM. Slomovitz B, et al. Among authors: coleman r. Gynecol Oncol. 2020 Mar;156(3):715-725. doi: 10.1016/j.ygyno.2019.12.033. Epub 2020 Jan 20. Gynecol Oncol. 2020. PMID: 31969252 Review.
Exploring and comparing adverse events between PARP inhibitors.
LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. LaFargue CJ, et al. Among authors: coleman rl. Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1. Lancet Oncol. 2019. PMID: 30614472 Free PMC article. Review.
DNA Damage Repair Inhibitors-Combination Therapies.
Smith G, Alholm Z, Coleman RL, Monk BJ. Smith G, et al. Among authors: coleman rl. Cancer J. 2021 Nov-Dec 01;27(6):501-505. doi: 10.1097/PPO.0000000000000561. Cancer J. 2021. PMID: 34904813 Review.
The forefront of ovarian cancer therapy: update on PARP inhibitors.
Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S. Mirza MR, et al. Among authors: coleman rl. Ann Oncol. 2020 Sep;31(9):1148-1159. doi: 10.1016/j.annonc.2020.06.004. Epub 2020 Jun 20. Ann Oncol. 2020. PMID: 32569725 Free article. Review.
Clear cell carcinoma of the endometrium.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Lorusso D, Coleman R, Vaughan MM, Takano M, Provencher D, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Kim JW, Candido Dos Reis FJ, Mariani A, Leitao MM Jr, Makker V, Rustum NA, Vergote I, Zannoni GF, Tan DSP, McCormack M, Bini M, Lopez S, Raspagliesi F, Panici PB, di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ. Bogani G, et al. Among authors: coleman r. Gynecol Oncol. 2022 Mar;164(3):658-666. doi: 10.1016/j.ygyno.2022.01.012. Epub 2022 Jan 19. Gynecol Oncol. 2022. PMID: 35063279 Review.
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A, Vindeløv SD, Chen M, Harris JR, Smith M, Nicacio LV, Teng MSL, Laenen A, Rangwala R, Manso L, Mirza M, Monk BJ, Vergote I; innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators. Coleman RL, et al. Lancet Oncol. 2021 May;22(5):609-619. doi: 10.1016/S1470-2045(21)00056-5. Epub 2021 Apr 9. Lancet Oncol. 2021. PMID: 33845034 Clinical Trial.
3,232 results